Perrigo PRGO reported adjusted earnings of 60 cents per share in the first quarter of 2025, beating the Zacks Consensus Estimate of 56 cents. The reported figure increased 107% year over year, primarily driven by improved margins and lower variable expenses.

Net sales declined 3.5% year over year to $1.04 billion, missing the Zacks Consensus Estimate of $1.08 billion. The downside was due to the loss of sales stemming from exited businesses and product lines, and unfavorable currency movements.

During the quarter, sales dropped 2% year over year on account of exited businesses and product lines and another 1.2% from unfavorable currency movement. At constant currency (excluding foreign currency translation), sales fell 2.4%. Organic net sales (excluding the effects of acquisitions and divestitures and the impact of currency) declined 0.4%.

More on PRGO’s Earnings

Perrigo reports its results under the following segments: Consumer Self Care Americas (CSCA) and Consumer Self Care International (CSCI).

CSCA: The segment’s net sales in the quarter came in at $621 million, down 3.6% year over year. Though sales grew across the Nutrition and Upper Respiratory categories, they were more than offset by lost distribution in U.S. Store Brand, a tough comparison in Women's Health following last year’s Opill launch, and lower sales in the Digestive Health category. Organic net sales also declined 3.6%. The reported segment sales missed the Zacks Consensus Estimate of $657 million and our model estimate of $638 million.

CSCI: The segment reported net sales of $423 million, down 3.4% from the year-ago period’s levels due to unfavorable impact from divested businesses, exited product lines and currency translation. At constant currency rates, sales were down 0.6% year over year. Organically, sales increased 4.5%. CSCI sales missed both the Zacks Consensus Estimate and our model estimate of $432 million and $434 million, respectively.

PRGO’s 2025 Guidance

Perrigo widened its full-year sales outlook due to macroeconomic uncertainty, including the potential impact of new tariffs. It now expects total net sales growth in the range of 0-3% year over year, compared to the prior guidance of 1-3%.

While PRGO expects tariffs to raise costs, especially in its Oral Care segment that relies heavily on Chinese sourcing, it believes the impact will be manageable. With 85% of its finished goods produced in the United States, the company plans to offset most of the pressure through price adjustments, shifting production to domestic facilities and other supply chain strategies. These reassurances likely contributed to the 5% rise in Perrigo shares during premarket trading.

Story Continues

Year to date, shares of Perrigo have lost 4% against the industry’s 4% growth.Zacks Investment Research

Image Source: Zacks Investment Research

Despite the revision in the top line, Perrigo reiterated all other 2025 financial targets, including an adjusted EPS range of $2.90 to $3.10, an adjusted gross margin of around 40%, and adjusted operating margins near 15%.

PRGO’s Zacks Rank

Perrigo currently has a Zacks Rank #3 (Hold).

Perrigo Company plc PricePerrigo Company plc Price

Perrigo Company plc price | Perrigo Company plc Quote

Our Key Picks Among Biotech Stocks

Some better-ranked stocks from the industry are Puma Biotechnology PBYI, Elevation Oncology ELEV and Intellia Therapeutics NTLA. While PBYI sports a Zacks Rank #1 (Strong Buy) at present, ELEV and NTLA carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

Estimates for Puma Biotechnology’s 2025 EPS have increased from 52 cents to 54 cents over the past 60 days, while the same for 2026 has increased from 49 cents to 54 cents.

Puma’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 88.62%. Year to date, PBYI stock is down 2%.

In the past 60 days, estimates for Elevation Oncology’s 2025 loss per share have narrowed from 83 cents to 61 cents. Loss per share estimates for 2026 have narrowed from 88 cents to 44 cents during the same time. Year to date, shares of ELEV have declined 40%.

ELEV’s earnings beat estimates in two of the trailing four quarters while missing on the remaining occasions, the average surprise being 5.10%.

In the past 60 days, estimates for Intellia Therapeutics’ 2025 loss per share have improved from $4.75 to $4.62. During the same timeframe, estimates for 2026 loss per share have narrowed from $4.68 to $4.62.

Intellia’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 5.37%. The stock has lost 38% year to date.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Perrigo Company plc (PRGO):Free Stock Analysis Report

Puma Biotechnology, Inc. (PBYI):Free Stock Analysis Report

Intellia Therapeutics, Inc. (NTLA):Free Stock Analysis Report

Elevation Oncology, Inc. (ELEV):Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments